• Romidepsin (FK228): Applied HDAC Inhibition in Cancer Assays

  2026-06-17

  Romidepsin (FK228) empowers oncology researchers with precise, selective HDAC inhibition, reshaping chromatin states and sensitizing cells to combination therapies. This article delivers actionable workflows, troubleshooting insights, and translational tips for maximizing Romidepsin’s effect in epigenetic and spliceosome-focused cancer research.

• BRD4770: Applied Workflows for G9a Histone Methyltransferase

  2026-06-17

  BRD4770 is a validated G9a histone methyltransferase inhibitor, enabling precise modulation of H3K9 methylation and cellular senescence in cancer models. This article delivers actionable protocols, troubleshooting insights, and advanced applications to help researchers maximize the reliability and impact of BRD4770 in epigenetic and cancer biology workflows.

• DiscoveryProbe™ Metabolism-related Compound Library: Practic

  2026-06-16

  The DiscoveryProbe™ Metabolism-related Compound Library (SKU: L1032) provides a standardized, rigorously validated set of 493 compounds for metabolic research applications, supporting robust and reproducible metabolic enzyme and pathway studies. It is designed strictly for in vitro and ex vivo workflows and should not be used in diagnostic or clinical settings.

• Apicidin: A Precision Histone Deacetylase Inhibitor for Epig

  2026-06-16

  Apicidin, a potent and selective histone deacetylase inhibitor, enables advanced interrogation of chromatin regulation and cytotoxicity in both cancer and reproductive models. Discover optimized protocol parameters, troubleshooting strategies, and actionable insights for leveraging Apicidin in high-impact bench research, with direct translation from recent mechanistic studies.

• Recombinant Annexin V Expression: Enabling Apoptosis Detecti

  2026-06-15

  This article analyzes Brumatti et al.'s methodological advancements in expressing and purifying recombinant annexin V for the sensitive detection of apoptotic cells via membrane phosphatidylserine exposure. The study's robust protocol offers increased reliability and scalability for apoptosis research, with implications for membrane biology and inflammation studies.

• Disrupting the c-MYC-G9a-FTH1 Axis in Breast Cancer via BRD4

  2026-06-15

  The referenced study demonstrates that co-targeting BRD4 and RAC1 suppresses breast cancer growth and stemness by disrupting the c-MYC-G9a-FTH1 axis and downregulating HDAC1. These mechanistic insights highlight the pivotal role of epigenetic regulation in tumorigenesis and underscore the utility of G9a histone methyltransferase inhibitors in cancer biology research.

• Nicotinamide Riboside Chloride (NIAGEN): Mechanistic Foundat

  2026-06-14

  Nicotinamide Riboside Chloride (NIAGEN) is a validated NAD+ booster that enhances oxidative metabolism and supports metabolic dysfunction research. Rigorous preclinical evidence confirms its utility in neurodegenerative disease models, including Alzheimer's disease, by elevating intracellular NAD+ and modulating sirtuin activity.

• Anti Reverse Cap Analog: Boosting Synthetic mRNA Translation

  2026-06-13

  Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, revolutionizes synthetic mRNA workflows by ensuring orientation-specific capping and doubling translational efficiency versus traditional cap analogs. Discover how ARCA streamlines in vitro transcription, maximizes mRNA stability, and overcomes common bottlenecks in protein expression and therapeutic mRNA research.

• Primidone (Mysoline): Protocols & Innovations in Translation

  2026-06-12

  Primidone (Mysoline) is transforming experimental neurobiology and disease modeling through dual TRPM3 and RIPK1 inhibition, providing robust workflows for ALS, pain, and neurodevelopmental disorder research. This article delivers hands-on protocol guidance, troubleshooting strategies, and actionable insights drawn directly from recent structural breakthroughs and translational studies.

• LY2109761: Advancing TGF-β Dual Inhibition in Translational

  2026-06-12

  Explore the mechanistic rationale and translational strategy behind LY2109761, a dual TGF-β receptor inhibitor. This thought-leadership article bridges molecular insight with actionable guidance for researchers targeting cancer progression, radiosensitivity, and fibrosis, referencing current literature and APExBIO's product expertise.

• Minocycline HCl: Redefining Neuroinflammation Assays with Ad

  2026-06-11

  Explore how Minocycline HCl enables next-generation neuroinflammation and regenerative medicine research. This in-depth article reveals assay design strategies and practical implications of scalable EV biomanufacturing, uniquely positioning Minocycline hydrochloride for advanced cellular signaling and translational applications.

• ETV5, Epigenetic Regulation, and EZH2 Inhibition in Cancer P

  2026-06-11

  This study provides a comprehensive pan-cancer analysis of the transcription factor ETV5, highlighting its role in tumor progression and its regulatory relationship with epigenetic modification, particularly EZH2. Notably, the research demonstrates that ETV5 enhances cell proliferation and reduces sensitivity to EZH2 inhibition, offering new insights for cancer epigenetics research and targeted therapy.

• CUDC-907: Technical Guidance for Dual PI3K and HDAC Inhibiti

  2026-06-10

  CUDC-907 provides a well-characterized dual PI3K and HDAC inhibitor for in vitro research targeting cell signaling and cell cycle regulation in oncology models. It is best suited to controlled laboratory settings and should not be used for diagnostic or clinical applications.

• Romidepsin (FK228) as a Precision Epigenetic Modulator in Tu

  2026-06-10

  Explore how Romidepsin (FK228) uniquely reactivates silenced tumor suppressor genes via targeted epigenetic modulation, distinguishing itself as a potent HDAC inhibitor for advanced cancer research. This article provides in-depth mechanistic insights and practical assay guidance for researchers.

• SMYD2 Inhibition with AZ505 Attenuates Cisplatin-Induced Ren

  2026-06-09

  The reference study demonstrates that pharmacological inhibition of SMYD2, particularly using AZ505, significantly reduces renal fibrosis and inflammation in a cisplatin-induced chronic kidney disease (CKD) model. These findings highlight SMYD2 as a promising target for therapeutic intervention in CKD and offer new mechanistic insights into epigenetic contributions to renal pathology.

16734 records 1/1116 page Next 12345 下5页 Last page